<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Sch of Molecular. Genetics &amp; Pop Health</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1C2EEA30-8EDC-4335-B896-240E712D2D9C"><gtr:id>1C2EEA30-8EDC-4335-B896-240E712D2D9C</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Mabbott</gtr:surname><gtr:orcidId>0000-0001-7395-1796</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8087A3C3-09A8-4495-8205-03AF95BFFB0E"><gtr:id>8087A3C3-09A8-4495-8205-03AF95BFFB0E</gtr:id><gtr:firstName>Jean</gtr:firstName><gtr:surname>Manson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2F797911-7091-40AF-B816-7AC69B99B44F"><gtr:id>2F797911-7091-40AF-B816-7AC69B99B44F</gtr:id><gtr:firstName>Rona</gtr:firstName><gtr:surname>Barron</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700640"><gtr:id>969E00C9-0449-4BD0-BBE9-8DE5F8134F08</gtr:id><gtr:title>Assessing the risk of transmission of vCJD via blood transfusion and identifying potential for diagnosis and prevention</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700640</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The recent announcement of a fourth possible transmission of variant Creutzfeldt-Jakob disease (vCJD) through blood transfusion raises concern that an epidemic of vCJD could be sustained through human to human transmission. While transmission from clinical cases of vCJD is not likely to result in a self-sustaining epidemic, current concern over the level of pre or sub-clinical vCJD in the population raises this as an important issue for risk assessment and disease prevention. This programme of work addresses the major issues surrounding the transmission of vCJD via transfusion of blood or blood products. Using our extensive expertise, our unique murine models of TSE disease and access to important samples from blood transfusion vCJD transmissions (made available to us by the National CJD Surveillance Unit) we aim to assess the risk of transmission of vCJD by blood and to define whether modifications in vCJD have occurred during these human-to-human transmission of vCJD, which may affect host range and pathogenicity. In order to assess the risk posed to individuals with different PrP genotypes, we aim to establish how polymorphisms in the PrP gene influence human to human transmissions of vCJD. We will also establish, using our well-defined animal models, where and when the vCJD agent infects the blood stream. 
Using our extensive expertise, unique resources, access to critical vCJD samples and our well defined TSE disease models the research in this proposal aims to address the urgent issues regarding the transmission of vCJD via blood transfusion. Experiments will be performed to answer the following questions:
-Are the strain characteristics of the vCJD agent modified by human to human transmission via blood transfusion?
-How does host PrP influence the human to human transmission of vCJD?
-How does infection of the blood stream occur and what components are affected? 
This programme will provide an important basis for assessing the risk of vCJD transmission via blood transfusion, and for developing accurate diagnostic tests to prevent further human to human transmission of vCJD.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2636521</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public lecture on Prion Diseases</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7392CCF6-08E9-420C-8888-E24C54B293A8</gtr:id><gtr:impact>Public lecture to inform on the current situation on vCJD</gtr:impact><gtr:outcomeId>56c1f8f3b314b2.84079809</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medical Detective Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>936C9D65-8CA7-47BE-94FF-F0775E47E188</gtr:id><gtr:impact>100 members of the public attended this public lecture and participated in the discussion afterwards

There have been emails from attendees requesting further information and a student has requested a placement.</gtr:impact><gtr:outcomeId>ShRvSZhpyCA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Careers event for S4 secondary pupils</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9C600CA5-E493-4B4D-8EF2-14B41A7697A4</gtr:id><gtr:impact>Careers workshop for S4 pupils. Approx 50 pupils attended and had discussions and questions over biological science careers. The school gave an update to say that pupils were interested and requested information on work experience/placement programs as a result.</gtr:impact><gtr:outcomeId>58c7c5e31b5110.71182330</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prion 2016 chair and invited speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B9F0BD19-EEE5-441A-A8DE-B8BB323C7CB2</gtr:id><gtr:impact>invited talk to international meeting</gtr:impact><gtr:outcomeId>58bd4b2822fce3.86560366</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2067455</gtr:amountPounds><gtr:country>Spain, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department of Health</gtr:department><gtr:description>Department of Health</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>Government of Catalonia</gtr:fundingOrg><gtr:fundingRef>007/0195</gtr:fundingRef><gtr:id>AB7E1157-C61D-43B9-8A50-FFBB301E296B</gtr:id><gtr:outcomeId>A9xgckvRYEA</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1130627</gtr:amountPounds><gtr:country>Spain, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department of Health</gtr:department><gtr:description>Policy Research Programme Department of Health</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>Government of Catalonia</gtr:fundingOrg><gtr:fundingRef>PR-ST-1214-10003</gtr:fundingRef><gtr:id>E7F50A6A-49C0-4140-9BEA-8D3A8252F6E8</gtr:id><gtr:outcomeId>58b592225d9e97.39863739</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the British Neuroscience Advisory Board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B2D084AC-87EA-4B70-8AEF-27DC35ED8752</gtr:id><gtr:outcomeId>pz9cTFBTzRy</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the International Science Advisory Council of APRI</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EC8A2CF8-C123-48F2-A709-AFD4FD69AC86</gtr:id><gtr:impact>The importance of this committee which I now chair is to provide scientific knowledge and expertise to the growing scientific community of the APRI</gtr:impact><gtr:outcomeId>ZWNVcPTjyBh</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the CJD Sample Oversight Committee Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D3262943-3CBD-4956-9535-73F763BF4CC5</gtr:id><gtr:impact>The committee aims to facilitate the development of diagnostics for vCJD through working with developers and providing access to rare samples</gtr:impact><gtr:outcomeId>rkpScXXqDHh</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the European Food Safety Authority</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D4CAFFA9-AE06-4B36-A0C2-4D60C9C3A9E9</gtr:id><gtr:impact>involved in development of policy on prion diseases</gtr:impact><gtr:outcomeId>tLEj8xgWTLE</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the ACDP</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>563ADD82-4510-4134-A3A9-DE0AB64C09CD</gtr:id><gtr:impact>The Advisory Committee on Dangerous pathogens advises the UK government on all issues related to dangerous pathogens from situations, in the field, in health care and laboratory practice. I serve on the committee as the expert on the Transmissible Spongiform Encephalopathies</gtr:impact><gtr:outcomeId>bvz7Yv6fNjU</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the UK SEAC Advisory Body</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>864BE66C-6580-4D31-A01E-0AC6326DC27D</gtr:id><gtr:impact>Spongiform Encephalopathy Advisory Committee advised Government on all accept of the Transmissible Spongiform Encephalopathies throughout the BSE and vCJD epidemics</gtr:impact><gtr:outcomeId>RriG7TJeFFs</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO TSE Working Group</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>AE532E3A-1F4C-4592-94F9-2A985B1F1F2F</gtr:id><gtr:impact>developed policy on prion diseases</gtr:impact><gtr:outcomeId>qwPK2twTjcL</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D48B6720-6A35-4463-BB70-C41AC0EC89E3</gtr:id><gtr:title>Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be30e536c69b9bcb232a510dc483d354"><gtr:id>be30e536c69b9bcb232a510dc483d354</gtr:id><gtr:otherNames>Bishop MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12920_20_23449776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A382B951-FB03-43B8-9645-780B0D92617F</gtr:id><gtr:title>Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be30e536c69b9bcb232a510dc483d354"><gtr:id>be30e536c69b9bcb232a510dc483d354</gtr:id><gtr:otherNames>Bishop MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>kDZDMsoNknm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C491FC6-AF71-400D-A5FF-5D68D459C77F</gtr:id><gtr:title>No major change in vCJD agent strain after secondary transmission via blood transfusion.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be30e536c69b9bcb232a510dc483d354"><gtr:id>be30e536c69b9bcb232a510dc483d354</gtr:id><gtr:otherNames>Bishop MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>WoXTwiZT4dR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE453C8F-4CF2-4EAB-81E2-3DE4883B05EE</gtr:id><gtr:title>B cell-specific S1PR1 deficiency blocks prion dissemination between secondary lymphoid organs.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bf108f93a0fafc59f36df35e5c04fb2"><gtr:id>8bf108f93a0fafc59f36df35e5c04fb2</gtr:id><gtr:otherNames>Mok SW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_12920_20_22504650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E9B70A8-A05A-44B7-A872-28CCA7C1AB0F</gtr:id><gtr:title>Variably protease-sensitive prionopathy, a unique prion variant with inefficient transmission properties.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06d2584ebbcc5853cd21c01b4c7378c8"><gtr:id>06d2584ebbcc5853cd21c01b4c7378c8</gtr:id><gtr:otherNames>Diack AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>56c1fc747d1ec4.04272416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB101B6F-E0F5-412B-8947-355A5654B05B</gtr:id><gtr:title>Variant CJD. 18 years of research and surveillance.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06d2584ebbcc5853cd21c01b4c7378c8"><gtr:id>06d2584ebbcc5853cd21c01b4c7378c8</gtr:id><gtr:otherNames>Diack AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>5675dda154528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09DFADCD-9AA8-4F6B-8057-F615CA1B6ACC</gtr:id><gtr:title>Constant transmission properties of variant Creutzfeldt-Jakob disease in 5 countries.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06d2584ebbcc5853cd21c01b4c7378c8"><gtr:id>06d2584ebbcc5853cd21c01b4c7378c8</gtr:id><gtr:otherNames>Diack AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>56c1fc75aa6ec3.04552877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BC4DCC5-AB67-4211-96BB-04F8E488A514</gtr:id><gtr:title>Prions and Diseases</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a9d543e8ed9a568c50e54348f90af1b"><gtr:id>0a9d543e8ed9a568c50e54348f90af1b</gtr:id><gtr:otherNames>Diack A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-1-4614-5337-6</gtr:isbn><gtr:outcomeId>doi_55f944944b159005</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700640</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>